 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Leukemia - Acute Promyelocytic Leukemia
|
|
Phase III Trial of Expanded Umbilical Cord Blood (StemEx®) for Treatment of Hematologic Malignancies Announced (6/17/2009)
Researchers from the University of Pittsburgh and Gamida Cell announced that the University of Pittsburgh would be participating in an international multicenter Phase III study of StemEx® for the treatment of hematologic malignancies. There are currently 15 U.S. centers and 11 centers in Europe and Israel participating in this study. This study is classified as a Phase III study but, because it is not randomized, patients will be compared to matched historical controls.
Guidelines Published for the Treatment of Acute Promyelocytic Leukemia (10/8/2008)
Researchers affiliated with the European LeukemiaNet have published guidelines for the management of acute promyelocytic leukemia (APL). These guidelines were published in an early online manuscript in Blood on September 23, 2008.
Tamibarotene Receives Orphan Drug Designation (11/5/2007)
The United States Food and Drug Administration (FDA) has granted Innovive Pharmaceuticals, Inc. orphan drug designation for their agent tamibarotene for the treatment of acute promyelocytic leukemia (APL). The indication of the designation is for the treatment of APL that has relapsed or is refractory to all-trans-retinoic acid (ATRA) and arsenic trioxide.
Atovaquone Effective Prophylaxis for Pneumocystis carinii Pneumonia in Children (4/10/2007)
Researchers from St Jude Children’s Research Center have reported that atovaquone (Mepron®, Malarone®) is effective prophylaxis against Pneumocystis carinii in children with leukemia. The details of this study appeared in the April 15, 2007 issue of Cancer.
Single-Agent Arsenic Trioxide Very Effective for Treatment of APL (3/27/2006)
Researchers from India have reported that single-agent arsenic trioxide (ATO), without ATRA (all-trans retinoic acid) and combination chemotherapy, results in an event-free survival of 75% in patients with acute promyelocytic leukemia (APL). The details of this phase II study were reported in the April 1, 2006 issue of Blood.
Mylotarg® Effective for Relapsed Acute Promyelocytic Leukemia (APL) (9/29/2004)
Researchers from Italy have reported that gemtuzumab ozogamicin (Mylotarg®) “is highly effective as a single-agent treatment for patients with molecularly relapsed APL including those with advanced disease”. The details of this report appeared in the October 1, 2004 issue of Blood.
Treatment of Elderly Patients with APL is Highly Effective (8/17/2004)
Researchers from Spain have reported that 79% of elderly patients (ages 60-83) with acute promyelocytic leukemia (APL) are alive and disease-free 6 years after diagnosis when treated with anthracyclines and ATRA. These authors suggest that elderly patients have better risk disease than younger patients with APL and should be treated aggressively for optimal results. The details of this report appeared as an advanced on line publication on August 3, 2004 in Blood.
ATRA in Consolidation Phase of Treatment of APL Improves Outcomes (3/24/2004)
Researchers from Spain have reported that patients with acute promyelocytic leukemia (APL) benefit from a risk adapted strategy that combines all-trans-retinoic acid (ATRA) in induction and consolidation. The details of this cooperative group study appeared in the February 15, 2004 issue of Blood.
Three-Four Consolidation Courses Decreases Relapses in AML with inv(16)t(16;16) (3/22/2004)
Researchers affiliated with CALGB have reported that patients with acute myeloid leukemia (AML) who have inv(16)(p13q22) or t(16;16)(p13;q22) cytogenetic abnormalities, inv(16)t(16;16), benefit from 3-4 cycles of high-dose cytarabine (HDAC) consolidation. The report was published in the March 15, 2004 issue of the Journal of Clinical Oncology.
Arsenic Trioxide and ATRA Highly Effective for Remission Induction of APL (12/12/2003)
Chinese and French researchers have reported that the combination of all trans-retinoic acid (ATRA) and arsenic trioxide is a very effective induction regimen which improves disease-free survival for patients with acute promyelocytic leukemia (APL).
1 The results of a randomized trial comparing arsenic trioxide alone, ATRA alone or the combination of arsenic trioxide and ATRA suggests synergism between these two drugs. The results of this trial were presented at the 45th annual meeting of the American Society of Hematology in December of 2003.
Arsenic Trioxide is Best Therapy for Relapsed Acute Promyelocytic Leukemia (4/24/2003)
Two recent reports demonstrate the effectiveness of arsenic trioxide in the treatment of APL. In 2000, the US Food and Drug Administration approved arsenic trioxide for the treatment of patients with acute promyelocytic leukemia (APL) who relapsed after primary treatment or failed to achieve an initial remission. The FDA approval was based on a multi-institutional clinical trial showing a 70% CR rate following treatment with arsenic trioxide in patients with APL in relapse.
Rituxan® and Campath® can be Safely Given Together with Encouraging Responses in Refractory Lymphoid Malignancies Expressing CD20 and CD52 (4/22/2003)
Researchers from the MD Anderson Cancer Center reported improved response rates in patients with refractory CLL or other B-cell malignancies that coexpressed CD20 and CD52 when treated with combined Rituxan® (rituximab) and (Campath®) alemtuzumab for the treatment of patients with refractory chronic lymphocytic leukemia (CLL) or other B-cell malignancies. These reported favorable results were reported in the May 1, 2003 issue of
Blood.
Long Term Follow-up Confirms Importance of ATRA in Curing Acute Promyelocytic Leukemia (12/5/2002)
All-trans retinoic acid (ATRA) has become an important part of the treatment regimen for patients with acute promyelocytic leukemia (APL). However, the optimal use of this agent has not been entirely clear. It now appears that it is important to include ATRA in both the induction and maintenance phases of treatment. The long term follow-up results of a large inter-group trial were published in the December 15, 2002 issue of
Blood. This trial evaluated the durability of responses that were previously reported.
|
|
Patient Home
